Production and characterization of monoclonal antibodies specific for canine CD138 (syndecan‐1) for nuclear medicine preclinical trials on spontaneous tumours
- 14 April 2016
- journal article
- research article
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 15 (3) , 932-951
Abstract
We isolated 11 antibodies specific for canine CD138 (cCD138) to validate the interest of CD138 antigen targeting in dogs with spontaneous mammary carcinoma. The affinity of the monoclonal antibodies in the nanomolar range is suitable for immunohistochemistry and nuclear medicine applications. Four distinct epitopes were recognized on cCD138 by this panel of antibodies. CD138 expression in canine healthy tissues is comparable to that reported in humans. CD138 is frequently expressed in canine mammary carcinomas corresponding to the human triple negative breast cancer subtype, with cytoplasmic and membranous expression. In canine diffuse large B‐cell lymphoma, CD138 expression is associated with the ‘non‐germinal center’ phenotype corresponding to the most aggressive subtype in humans. This homology of CD138 expression between dogs and humans confirms the relevance of tumour‐bearing dogs as spontaneous models for nuclear medicine applications, especially for the evaluation of new tumour targeting strategies for diagnosis by phenotypic imaging and radio‐immunotherapy.Keywords
This publication has 40 references indexed in Scilit:
- Prognostic significance of RSPO1, WNT1, P16, WT1, and SDC1 expressions in invasive ductal carcinoma of the breastWorld Journal of Surgical Oncology, 2013
- A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapiesCritical Reviews in Oncology/Hematology, 2013
- Treatment of Triple-Negative Breast Cancer Using Anti-EGFR–Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP InhibitorJournal of Nuclear Medicine, 2013
- Vascular Hyperpermeability, Angiogenesis, and Stroma GenerationCold Spring Harbor Perspectives in Medicine, 2011
- Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumorsEJNMMI Research, 2011
- Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeabilityJournal of Angiogenesis Research, 2010
- Comparative expression pathway analysis of human and canine mammary tumorsBMC Genomics, 2009
- Prognostic markers in triple‐negative breast cancerCancer, 2006
- Soluble syndecan‐1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survivalBritish Journal of Haematology, 2005
- Preclinical evaluation of intravenously administered 111in- and 90y-labeled b72.3 immunoconjugate (GYK-DTPA) in beagle dogsNuclear Medicine and Biology, 1993